201 related articles for article (PubMed ID: 22675576)
1. LSK derived LSK- cells have a high apoptotic rate related to survival regulation of hematopoietic and leukemic stem cells.
Peng C; Chen Y; Shan Y; Zhang H; Guo Z; Li D; Li S
PLoS One; 2012; 7(6):e38614. PubMed ID: 22675576
[TBL] [Abstract][Full Text] [Related]
2. Targeting of GSK3β promotes imatinib-mediated apoptosis in quiescent CD34+ chronic myeloid leukemia progenitors, preserving normal stem cells.
Reddiconto G; Toto C; Palamà I; De Leo S; de Luca E; De Matteis S; Dini L; Passerini CG; Di Renzo N; Maffia M; Coluccia AM
Blood; 2012 Mar; 119(10):2335-45. PubMed ID: 22262776
[TBL] [Abstract][Full Text] [Related]
3. Effects of dasatinib on SRC kinase activity and downstream intracellular signaling in primitive chronic myelogenous leukemia hematopoietic cells.
Konig H; Copland M; Chu S; Jove R; Holyoake TL; Bhatia R
Cancer Res; 2008 Dec; 68(23):9624-33. PubMed ID: 19047139
[TBL] [Abstract][Full Text] [Related]
4. The Alox5 gene is a novel therapeutic target in cancer stem cells of chronic myeloid leukemia.
Chen Y; Li D; Li S
Cell Cycle; 2009 Nov; 8(21):3488-92. PubMed ID: 19823023
[TBL] [Abstract][Full Text] [Related]
5. Retention but significant reduction of BCR-ABL transcript in hematopoietic stem cells in chronic myelogenous leukemia after imatinib therapy.
Abe A; Minami Y; Hayakawa F; Kitamura K; Nomura Y; Murata M; Katsumi A; Kiyoi H; Jamieson CHM; Wang JYJ; Naoe T
Int J Hematol; 2008 Dec; 88(5):471-475. PubMed ID: 19039626
[TBL] [Abstract][Full Text] [Related]
6. Imatinib (ST1571) provides only limited selectivity for CML cells and treatment might be complicated by silent BCR-ABL genes.
Jiang G; Yang F; Li M; Weissbecker K; Price S; Kim KC; La Russa VF; Safah H; Ehrlich M
Cancer Biol Ther; 2003; 2(1):103-8. PubMed ID: 12673129
[TBL] [Abstract][Full Text] [Related]
7. Physiologic hypoxia promotes maintenance of CML stem cells despite effective BCR-ABL1 inhibition.
Ng KP; Manjeri A; Lee KL; Huang W; Tan SY; Chuah CT; Poellinger L; Ong ST
Blood; 2014 May; 123(21):3316-26. PubMed ID: 24705490
[TBL] [Abstract][Full Text] [Related]
8. beta-Catenin is essential for survival of leukemic stem cells insensitive to kinase inhibition in mice with BCR-ABL-induced chronic myeloid leukemia.
Hu Y; Chen Y; Douglas L; Li S
Leukemia; 2009 Jan; 23(1):109-16. PubMed ID: 18818703
[TBL] [Abstract][Full Text] [Related]
9. Molecular and functional analysis of the stem cell compartment of chronic myelogenous leukemia reveals the presence of a CD34- cell population with intrinsic resistance to imatinib.
Lemoli RM; Salvestrini V; Bianchi E; Bertolini F; Fogli M; Amabile M; Tafuri A; Salati S; Zini R; Testoni N; Rabascio C; Rossi L; Martin-Padura I; Castagnetti F; Marighetti P; Martinelli G; Baccarani M; Ferrari S; Manfredini R
Blood; 2009 Dec; 114(25):5191-200. PubMed ID: 19855080
[TBL] [Abstract][Full Text] [Related]
10. Expansion of Bcr-Abl-positive leukemic stem cells is dependent on Hedgehog pathway activation.
Dierks C; Beigi R; Guo GR; Zirlik K; Stegert MR; Manley P; Trussell C; Schmitt-Graeff A; Landwerlin K; Veelken H; Warmuth M
Cancer Cell; 2008 Sep; 14(3):238-49. PubMed ID: 18772113
[TBL] [Abstract][Full Text] [Related]
11. Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity.
Corbin AS; Agarwal A; Loriaux M; Cortes J; Deininger MW; Druker BJ
J Clin Invest; 2011 Jan; 121(1):396-409. PubMed ID: 21157039
[TBL] [Abstract][Full Text] [Related]
12. Dual targeting of p53 and c-MYC selectively eliminates leukaemic stem cells.
Abraham SA; Hopcroft LE; Carrick E; Drotar ME; Dunn K; Williamson AJ; Korfi K; Baquero P; Park LE; Scott MT; Pellicano F; Pierce A; Copland M; Nourse C; Grimmond SM; Vetrie D; Whetton AD; Holyoake TL
Nature; 2016 Jun; 534(7607):341-6. PubMed ID: 27281222
[TBL] [Abstract][Full Text] [Related]
13. Effective and selective inhibition of chronic myeloid leukemia primitive hematopoietic progenitors by the dual Src/Abl kinase inhibitor SKI-606.
Konig H; Holyoake TL; Bhatia R
Blood; 2008 Feb; 111(4):2329-38. PubMed ID: 18056843
[TBL] [Abstract][Full Text] [Related]
14. Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice.
Hu Y; Swerdlow S; Duffy TM; Weinmann R; Lee FY; Li S
Proc Natl Acad Sci U S A; 2006 Nov; 103(45):16870-5. PubMed ID: 17077147
[TBL] [Abstract][Full Text] [Related]
15. Donor hematopoietic stem cells confer long-term marrow reconstitution by self-renewal divisions exceeding to that of host cells.
Roy S; Javed S; Jain SK; Majumdar SS; Mukhopadhyay A
PLoS One; 2012; 7(12):e50693. PubMed ID: 23227199
[TBL] [Abstract][Full Text] [Related]
16. Spred1 deficit promotes treatment resistance and transformation of chronic phase CML.
Qiao J; Liang C; Zhao D; Nguyen LXT; Chen F; Suo S; Hoang DH; Pellicano F; Rodriguez IR; Elhajmoussa Y; Ghoda L; Yoshimura A; Stein AS; Ali H; Koller P; Perrotti D; Copland M; Han A; Zhang BA; Marcucci G
Leukemia; 2022 Feb; 36(2):492-506. PubMed ID: 34564700
[TBL] [Abstract][Full Text] [Related]
17. Effective targeting of quiescent chronic myelogenous leukemia stem cells by histone deacetylase inhibitors in combination with imatinib mesylate.
Zhang B; Strauss AC; Chu S; Li M; Ho Y; Shiang KD; Snyder DS; Huettner CS; Shultz L; Holyoake T; Bhatia R
Cancer Cell; 2010 May; 17(5):427-42. PubMed ID: 20478526
[TBL] [Abstract][Full Text] [Related]
18. Editorial: CML HSCs: Are the True Enemies for the Patient?
Mancini M
Curr Drug Targets; 2017; 18(4):376. PubMed ID: 28264644
[No Abstract] [Full Text] [Related]
19. Frequency of acute myeloid leukaemia-associated mouse chromosome 2 deletions in X-ray exposed immature haematopoietic progenitors and stem cells.
Olme CH; Brown N; Finnon R; Bouffler SD; Badie C
Mutat Res; 2013 Aug; 756(1-2):119-26. PubMed ID: 23665297
[TBL] [Abstract][Full Text] [Related]
20. Molecular and cellular bases of chronic myeloid leukemia.
Chen Y; Peng C; Li D; Li S
Protein Cell; 2010 Feb; 1(2):124-32. PubMed ID: 21203982
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]